Abstract
BTG2/TIS21/PC3 (B cell translocation gene 2) has been known as a p53 target gene and functions as a tumor suppressor in carcinogenesis of thymus, prostate, kidney, and liver. Although it has been known that the expression of BTG2/TIS21/PC3 is induced during chemotherapy-mediated apoptosis in cancer cells, a role of BTG2/TIS21/PC3 in cell death remains to be elucidated. In this study, the mechanism and role of BTG2 involved in the enhancement of doxorubicin (DOXO)-induced cell death were examined. Treatment of HeLa cells with DOXO revealed apoptotic phenomena, such as chromatin condensation and cleavage of poly(ADP-ribose) polymerase and lamin A/C with concomitant increase of BTG2/TIS21/PC3 expression. Employing infections of Ad-TIS21 virus and lentivirus with short hairpin RNA to BTG2, the effect of BTG2/TIS21/PC3 on the DOXO-induced apoptosis of HeLa cells and liver cancer cells was evaluated. Not only short hairpin RNA-BTG2 but also N-acetyl-l-cysteine significantly reduced the DOXO-induced HeLa cell death and generation of H2O2. Moreover, forced expression of BTG2/TIS21/PC3 using adenoviral vector augmented DOXO-induced cancer cell death concomitantly with increase of manganese-superoxide dismutase but not catalase, CuZnSOD, and glutathione peroxidase 1. The increased apoptosis by forced expression of BTG2/TIS21/PC3 could be inhibited by N-acetyl-l-cysteine and polyethylene glycol-catalase. These results therefore suggest that BTG2/TIS21/PC3 works as an enhancer of DOXO-induced cell death via accumulation of H2O2 by up-regulating manganese-superoxide dismutase without any other antioxidant enzymes. In summary, BTG2/TIS21/PC3 enhances cancer cell death by accumulating H2O2 via imbalance of the antioxidant enzymes in response to chemotherapy.
TIS21 (12-O-tetradecanoylphorbol-13-acetate-inducible sequence 21) was first identified as one of immediate early genes (1) in mice 3T3 fibroblasts when treated with 12-O-tetradecanoylphorbol-13-acetate (2). Since then, PC3 (pheochromocytoma cell 3) was isolated as an immediate early response gene when activated by nerve growth factor at the onset of neuronal differentiation in rat PC12 cells (3). The human homolog of TIS21, named BTG2 (B cell translocation gene 2), was cloned from a cDNA library of human lymphoblastoid cells as a gene associated with DNA damage response and contains p53 response elements in its 5′-flanking (–74 to –112) region (4).
We previously reported that TIS21 expression was low in thymic carcinoma developed in the SV40 large T antigen transgenic mice but high in normal thymus, suggesting anticarcinogenic activity of TIS21 in thymus (5). Expressions of TIS21 in renal proximal tubule and prostate acini are lost also in the renal carcinoma and the early stage of carcinogenesis in prostate (6, 7), respectively. Consistent with these findings, Boiko et al. (8) recently ascertained BTG2 as a tumor suppressor by showing that BTG2 is a major downstream effector of p53-dependent proliferation arrest of mouse and human fibroblasts transduced with oncogenic Ras and that repression of BTG2 regulates the activities of cyclin D1 and cyclin E and phosphorylation of pRB, thus inducing neoplastic transformation of primary human fibroblasts. TIS21 has been known to work also independently of pRB and p53 in cancer cells regulating G1/S arrest and G2/M arrest by inhibiting synthesis of cyclin E and cdk4 (9), as well as interaction with cyclin B1 and the cdk1 complex (10), respectively. Moreover, persistent expression of TIS21 induces the loss of mitochondrial membrane potential differences in U937 cells (11), and transfection of TIS21 gene to Huh7 hepatoma cells significantly reduces in vivo and in vitro tumorigenesis by inhibiting feedback regulation between cyclin B1 and FoxM1 transcription factor (11), and the expression of BTG2 in human liver cancer is much lower than that of the surrounding tissues. Collectively, these findings indicate that TIS21 controls cellular process as an inhibitor of cell division cycle and a tumor suppressor, thus evading cancer development independent of p53.
The level of reactive oxygen species (ROS)2 is controlled by multiple interacting components. Among them, superoxide dismutase (SOD), glutathione peroxidase 1 (GPx), and catalase are the primary antioxidant enzymes in mammalian tissues (12, 13). SOD catalyzes dismutation of superoxide anion to hydrogen peroxide, which is further detoxified by catalase and GPx. In mammals, there are at least three forms of SOD: cytosolic CuZnSOD, extracellular ECSOD, and mitochondrial MnSOD. MnSOD knock-out mice die within 18 days after birth, suggesting that MnSOD is an essential enzyme (14). On the other hand, it is reported that MnSOD has the opposite effect, for instance, overexpression of SOD in Escherichia coli results in an increased sensitivity to paraquat and hyperoxia (15), as well as ionizing radiation caused by apparently increased generation of H2O2 (16). In addition, overexpression of MnSOD revealed higher sensitivity to ROS in human prostate carcinoma cells (17).
Although it has been known that the expression of BTG2/TIS21/PC3 is induced during chemotherapy-induced apoptosis in various cancer cells (18–20), the role of BTG2/TIS21/PC3 in cell death remains to be elucidated. Despite the fact that a large body of studies has consistently suggested that BTG2 functions as a tumor suppressor, BTG2–/– ES cells are more sensitive to DOXO when compared with BTG2+/+ ES cells (4). To our best knowledge, there is yet no report regarding how TIS21/BTG2 induces the apoptosis of cancer cells in response to chemotherapy. Therefore, we investigated, in the present study, the role of BTG2 in the process of DOXO-induced apoptosis of cancer cells and found that BTG2 enhanced DOXO-induced oxidative damage via imbalance of antioxidant enzymes and worked as a pro-apoptotic gene in the cell death process.
EXPERIMENTAL PROCEDURES
Cell Cultures—HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with heat-inactivated 10% (v/v) fetal bovine serum in a humidified atmosphere containing 5% CO2 at 37 °C. The medium was changed every other day. All of the doxorubicin treatments were performed in the culture medium (Dulbecco's modified Eagle's medium) containing 10% (v/v) fetal bovine serum. Immediately before treatment, the medium was removed and replaced with fresh medium.
Reagents—N-Acetyl-l-cysteine, PEG-catalase, and pyrogallol were purchased from Sigma-Aldrich. Doxorubicin was from Tocris Bioscience.
Nuclear Staining with Hoechst Dye—Staining was performed as described (21). In brief, control and treated cells (1 μg/ml doxorubicin for 24 h) were fixed with 3.7% (v/v) paraformaldehyde in phosphate-buffered saline for 10 min at room temperature and permeated with 0.1% Triton X-100 for 10 min at room temperature. The fixed cells were stained with Hoechst 33258 for 5 min, washed, and then examined by fluorescence microscopy (340-nm excitation and 510-nm barrier filter). Apoptotic cells were identified by the presence of highly condensed or fragmented nuclei.
Preparation of Cell Lysates and Western Blot Analysis—To prepare a total cell lysate, the cells were washed in ice-cold phosphate-buffered saline and lysed in 50 mm Tris, pH 7.4, containing 150 mm NaCl, 1 mm EDTA, 1 mm phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, 1 μg/ml leupeptin, 1 μg/ml pepstatin, 1 mm NaF, 1 mm sodium orthovanadate, 0.25% sodium deoxycholate, and 1% Nonidet P-40. The supernatants were collected after centrifugation at 10,000 × g for 10 min. 50-μg aliquots of protein samples were size-fractionated by electrophoresis and then transferred to nitrocellulose membrane. The membranes were immunoblotted with primary antibodies and horseradish peroxidase-conjugated anti-mouse IgG. The immunoblotted proteins were visualized by a chemiluminescence ECL system (Amersham Biosciences). The primary antibodies were purchased from the following sources: anti-lamin A/C and anti-HA from Cell Signaling; anti-PARP from Zymed Laboratories Inc.; anti-MnSOD, anti-GPx, and anti-catalase from Lab Frontier; anti-α-tubulin from Santa Cruz Biotechnology.
Lentiviral shRNA Production and in Vitro Transduction—PLKO.1 lentiviral vectors expressing shRNAs against BTG2 were purchased from Open Biosystems. For BTG2, five preformed constructs were obtained and tested to identify the constructs, which were able to achieve efficient knockdown using RT-PCR. Lentiviral vector stock was produced in 293T cells by transient cotransfection of shRNA construct together with pHR8.2R and pCMV-VSV-G helper constructs using Lipofectamine. The supernatants were harvested after 30 h and filtered through a 0.22-micron filter (Millipore) to remove any nonadherent 293T cells. Next, HeLa cells (5 × 104 in 35-mm-diameter culture dishes) were transduced with 1 ml of virus containing supernatant supplemented with 8 μg of Polybrene. The medium was changed 1 day postinfection, and fresh medium was applied for 2 days.
RT-PCR—Total cellular RNA was prepared by standard TRIzol-based methods. 1 μg of total RNA was reverse-transcribed with oligo(dT) using the Superscript II reverse transcriptase kit (Invitrogen), according to the manufacturer's protocol. RT product (1/50 volume) was applied to PCR. cDNA fragments of BTG2 (175 bp) and glyceraldehyde-3-phosphate dehydrogenase (195 bp) were amplified using the following primers: sense, 5′-CGAGCAGAGGCTTAAGGTCTTC-3′, and antisense, 5′-CTGGCTGAGTCCGATCTGG-3′ for BTG2; and sense, 5′-CCATGGAGAAGGCTGGGG-3′, and antisense, 5′-CAAAGTTGTCATGGATGACC-3′ for glyceraldehyde-3-phosphate dehydrogenase.
Measurement of Intracellular Hydrogen Peroxide and Superoxide Anion Concentration—The intracellular H2O2 concentration was measured by fluorescence-activated cell sorter analysis using 50 μm 2,7-dichlorodihydrofluorescein diacetate (H2-DCFDA) (D-399; Molecular Probes) in a cell culture system as described (22). In brief, the cells were pretreated with H2-DCFDA for 10 min prior to cell harvest. H2O2 generation was determined with FACScan (BD Biosciences) by measuring the fluorescence of dichlorodihydrofluorescein arising from the oxidation of H2-DCFDA. Nitro blue tetrazolium salt (NBT) forms a water-insoluble blue formazan when it reacts with intracellular superoxide, showing the degree of superoxide formation within the cell. Chromogenic detection of superoxide was performed using NBT as described (23). In brief, control cells and cells treated with 50 μm pyrogallol for 3 h were incubated with NBT (1.6 mg/ml) in Hanks' balanced salt solution. After a wash in methanol, formazan crystals were extracted with 560 μl of 2 m KOH and 480 μl of DMSO. Absorbance was measured at 575 nm. The results were expressed as A575 obtained from 106 cells.
Construction and Use of Adenoviral Vectors—Adenoviral vector expressing TIS21 (Ad-TIS21) was prepared as described (24). In brief, cDNA of TIS21 inserted into replication-defective E1- and E3-adenoviral vectors were transfected and then amplified in 293 human kidney epithelial cells. Adenovirus with bacterial β-galactosidase (Ad-β-Gal) was also prepared for control experiment.
MnSOD Activity Assay—To measure MnSOD activity, cells were collected with a rubber policeman and sonicated in cold 20 mm HEPES buffer, pH 7.2 (EGTA 1 mm, 210 mm mannitol, and 70 mm sucrose), followed by centrifugation at 1,500 × g for 5 min at 4 °C. The supernatant was subsequently centrifuged at 10,000 × g for 15 min at 4 °C. The resulting pellet was homogenized with HEPES buffer containing 0.1% Triton X-100 and subjected to MnSOD activity assay using a superoxide dismutase assay kit (SOD-560; Applied Bioanalytical Labs) according to the manufacturer's protocol. The activity of MnSOD was measured in the presence of 2 mm potassium cyanide, an inhibitor of CuZnSOD.
Statistics—The results were expressed as the means ± S.D. from three to four experiments performed independently. Paired Student's t test was performed where indicated, and p < 0.05 was considered significant.
RESULTS
Doxorubicin-induced Cell Death Accompanied with BTG2/TIS21 Expression—Doxorubicin is one of the well known chemotherapeutic agents and inducers of apoptosis in various tumor cells including HeLa cells (25). As reported, when HeLa cells were treated with DOXO, chromatin condensation, evidenced by Hoechst dye staining (Fig. 1A), and cleavages of PARP (substrate of caspase-3 and -7) and lamin A/C (substrate of caspase 6) were observed in dose-dependent manner (Fig. 1B). To investigate the possible involvement of BTG2 in DOXO-induced cell death, HeLa cells were exposed to DOXO for 24 h, and the time-dependent cleavage of lamin A/C (Fig. 1D) with a concomitant increase of BTG2 expression were observed in 12 h (Fig. 1C), suggesting that BTG2 may have a role in the process of DOXO-induced cell death.
BTG2/TIS21 Enhanced DOXO-induced Cell Death in Human Cancer Cell Lines—To examine the role of BTG2 in DOXO-induced cell death, HeLa cells were infected with HA-tagged Ad-TIS21 virus or Ad-β-Gal as the control. Infection of the cells with Ad-TIS21 virus (10–100 m.o.i.) significantly increased the number of cells with chromatin condensation in response to DOXO treatment, as compared with that of the control (Fig. 2A). Based on the data in Fig. 2A, HeLa cells were infected with viruses (50 m.o.i.) and then treated with DOXO, and the expression of TIS21 was examined by Western blot analysis using anti-HA antibody. As shown in Fig. 2B, Ad-TIS21 enhanced DOXO-induced cleavages of PARP and lamin A/C compared with those of the control. However, TIS21 itself did not induce the cleavages when the cells were treated with DOXO. To confirm the pro-apoptotic activity of TIS21 in DOXO-induced cell death, endogenous BTG2/TIS21 was down-regulated by using sh-BTG2/TIS21 RNA. Thus, HeLa cells were infected with either lentivirus of BTG2 shRNA (H4 or H5) or empty vector as a control, and the efficiency of knockdown was measured by RT-PCR. As shown in Fig. 2C, RT-PCR revealed down-regulation of BTG2 mRNA in the H4 or H5 infected cells, whereas the expression of glyceraldehyde-3-phosphate dehydrogenase was unaffected. Infection of the cells with sh-BTG2 or control lentiviral vector did not indicate any signs of cell death; however, infection with H4 or H5 significantly reduced the effect of DOXO on the cleavage of lamin A/C (Fig. 2C, right panel). Fig. 2 (A--C) clearly showed pro-apoptotic activity of BTG2 during DOXO-induced cell death in HeLa cells. The findings were unexpected, because BTG2–/– ES cells exhibited increased sensitivity to DOXO-induced cell death (4). To investigate whether the effect of BTG2 on DOXO-induced cell death is not a confined phenomenon in HeLa cells, human hepatocellular carcinoma cell lines Huh7, HepG2, and Hep3B were infected with Ad-TIS21 virus and then treated with IC50 concentrations of DOXO (26) to induce apoptosis. Fig. 2D showed that TIS21 augmented DOXO-induced cleavages of PARP and lamin A/C, compared with those of the Ad-β-Gal. These findings clearly proved the pro-apoptotic role of TIS21 not only in HeLa cells but also in the hepatoma cell lines.
BTG2/TIS21 Up-regulated Generation of H2O2 Induced by DOXO—Based on the report that DOXO produces ROS in cells (27), we first examined whether DOXO was indeed engaged in the apoptotic process of HeLa cells by producing ROS. As expected, ROS in the DOXO-treated HeLa cells was increased as compared with that of the control (Fig. 3A). To further confirm the involvement of ROS in the process, HeLa cells were pretreated with NAC (0–10 mm), a well known H2O2 scavenger, and apoptosis was then induced by DOXO. Fig. 3B shows that pretreatment of the cells with NAC-inhibited DOXO-induced cleavage of lamin A/C dose-dependently, indicating that ROS are indeed involved in cell death. Pretreatment with NAC also led to a dose-dependent decrease in the number of cells with condensed chromatin (data not shown). To investigate the possible involvement of ROS in pro-apoptotic function of BTG2 during DOXO-induced cell death, we first investigated the effect of TIS21/BTG2 overexpression on superoxide anion generator-induced cell death (28). HeLa cells were incubated with pyrogallol (PYRO; superoxide anion generator), and then NBT reduction by superoxide anion generated was examined. As shown in Fig. 3C, NBT reduction was dependent on the concentration of PYRO (upper panel), and superoxide anion generator-mediated cleavage of PARP was significantly reduced by pretreatment of NAC (lower panel), suggesting in vivo conversion of PYRO-induced superoxide anion to H2O2. When HeLa cells were first infected with 50 m.o.i. of Ad-TIS21 or Ad-β-Gal and then cell death was induced by treatment of the cells with PYRO (50 μm) for 48 h with or without NAC (5 mm) pretreatment, PYRO-induced cell death was enhanced by TIS21, as opposed to inhibition of the enhancement by NAC pretreatment. The finding strongly supports that TIS21 used H2O2 to regulate PYRO-induced cell death (Fig. 3D). Thus, employing BTG2 shRNA (H4 and H5) and empty vector as a control (Con) we then examined whether the pro-apoptotic effect of BTG2 on DOXO-induced cell death was associated with H2O2 generation. As shown in Fig. 3E, DOXO-induced H2O2 production was reduced by H4 and H5 infection, as compared with that of the control, indicating up-regulation of H2O2 generation by BTG2. To confirm the effect of BTG2/TIS21 on the generation of intracellular H2O2, the cells were infected Ad-TIS21 or Ad-β-Gal viruses, and apoptosis was then induced with DOXO treatment. Treatment of the cells with DOXO significantly increased the level of H2O2, and the overexpression of TIS21 further enhanced the H2O2 level compared with that of the Ad-β-Gal expression (Fig. 3F). TIS21 itself did not affect the generation of H2O2 but significantly enhanced DOXO-induced H2O2 generation. Pretreatment of the Ad-TIS21 or Ad-β-Gal-infected cells with NAC inhibited DOXO-induced H2O2 generation, indicating that TIS21 up-regulated DOXO-induced H2O2 production.
NAC Abolished Effect of BTG2/TIS21 on DOXO-induced Cell Death—Next, we examined whether the enhanced cell death by BTG2 was regulated by intracellular H2O2. Thus, HeLa cells infected with Ad-β-Gal or Ad-TIS21 were exposed to DOXO in the presence of NAC, and cell death was monitored by chromatin condensation. NAC pretreatment abolished the increase of chromatin condensation both in the cells infected with Ad-β-Gal or Ad-TIS21, although Ad-TIS21 infection increased the chromatin condensation more than that of Ad-β-Gal infection (Fig. 4A). Concomitantly, the cleavage of lamin A/C was enhanced after Ad-TIS21 infection, as compared with that of Ad-β-Gal, and NAC pretreatment significantly abolished the effect of Ad-TIS21 (Fig. 4B). The data strongly suggest that H2O2 generation may be the major downstream mediator of BTG2/TIS21 when it works as a pro-apoptotic molecule in DOXO-induced cell death.
BTG2/TIS21 Up-regulated Expression of MnSOD, but Not Other Antioxidant Enzymes—To investigate a mechanism involved in the significant increase of H2O2 in the DOXO-treated HeLa cells, we first examined the effects of DOXO on the expression of antioxidant enzymes. Treatment of HeLa cells with DOXO (0–1.0 μg/ml) for 12 h up-regulated the expression of MnSOD and CuZnSOD in dose-dependent manner, whereas the levels of GPx, catalase, and α-tubulin protein were not changed at all (Fig. 5A), strongly suggesting that the increase of H2O2 by DOXO treatment might be due to an imbalance of the coordinated expression of antioxidant enzymes. To investigate whether the up-regulation of MnSOD and CuZnSOD after DOXO treatment was due to the increase of BTG2/TIS21 in the cells, HeLa cells were infected with Ad-TIS21, and the expression of antioxidant enzymes was measured by Western blot analyses. As shown in Fig. 5B, infection of Ad-TIS21 itself increased MnSOD expression, and TIS21 enhanced the effect of DOXO on the increased expression of MnSOD without any changes of the other enzymes. Although expression of CuZnSOD was also up-regulated by DOXO treatment, the expression was not regulated by TIS21. At the same time, the activity of MnSOD was correlated with its protein level (Fig. 5C). All of the data strongly suggested that the up-regulation of H2O2 in the DOXO-treated HeLa cells might result from BTG2/TIS21-mediated imbalance of antioxidant enzyme expression. In addition, H4 and H5 sh-BTG2 prevented the effect of TIS21 on the DOXO-induced MnSOD expression (Fig. 5D), indicating that DOXO-induced MnSOD expression might be up-regulated by BTG2/TIS21. To verify the hypothesis that the increase of H2O2 in the DOXO-treated cells might have been due to an imbalance of the coordinated expressions of antioxidant enzymes, we investigated whether PEG-catalase, the membrane-permeable form (29), could protect cells from DOXO-induced apoptosis. Thus, HeLa cells were pretreated with PEG-catalase (0–1000 units/ml) for 12 h before DOXO treatment to balance the expression of MnSOD, and DOXO-induced cell death was then examined by immunoblot analysis. PEG-catalase inhibited the cleavage of lamin A/C induced by DOXO treatment (Fig. 5E). These data indicate that BTG2/TIS21 can augment DOXO-induced cell death via up-regulation of MnSOD, thereby resulting in an imbalance of the coordinated expression of antioxidant enzymes with an increase of H2O2. Therefore, an increased ratio of MnSOD/catalase appears to enhance DOXO-induced cell death.
No Protective Effect of NAC on DOXO-induced MEF Cell Death—Although the present findings indicate that BTG2 augments DOXO-induced cell death in HeLa cells, BTG2/PC3/TIS21 knock-out ES cells were known to be more sensitive to DOXO-induced cell death compared with wild type (4). To confirm the role of BTG2 in DOXO-induced cell death in ES cells, we employed our TIS21–/– MEF (24, 30, 31). As opposed to TIS21+/+ MEF, exposure of TIS21–/– MEF to DOXO demonstrated a lower number of viable cells, suggesting the anti-apoptotic role of TIS21 gene in MEF (Fig. 6A). To investigate whether the anti-apoptotic effect of BTG2 was related to antioxidant enzymes, expressions of MnSOD and catalase were examined in the TIS21–/– MEF (Fig. 6B). MnSOD, but not catalase, expression was lower in the TIS21–/– MEF than that of wild type MEF. Moreover, reconstitution of TIS21 gene by infection of TIS21–/– MEF with Ad-TIS21 virus, MnSOD, but not catalase, expression was regulated according to the level of Ad-TIS21 (0–10 m.o.i.). The phenomenon was in close accordance with our previous data (Fig. 5, B–D) that TIS21 itself up-regulated MnSOD expression and its activity. When the effect of TIS21 on ROS was evaluated, treatment of wild type MEF with DOXO generated more H2O2 than that of TIS21–/– MEF (Fig. 6C). However, it was significantly reduced by NAC pretreatment. When we compared the generation of H2O2 after DOXO treatment, the amount of H2O2 generated in wild type MEF was not lower than that of HeLa cells (Fig. 6D). These findings indicate that although TIS21 exhibited pro-apoptotic and anti-apoptotic activities in HeLa and MEF, respectively, TIS21 enhanced H2O2 generation in response to DOXO treatment both in HeLa and MEF cells via regulation of MnSOD.
To further characterize role of H2O2 in normal cells, we next examined the effect of oxidative stress in the DOXO-induced MEF cell death. In contrast to the protective role of NAC in DOXO-induced HeLa cell death (Fig. 3B), pretreatment of MEF with NAC failed to block DOXO-induced MEF cell death (Fig. 6E). Moreover, treatment of MEF with either NAC, H2O2 scavenger, or 100 μm pyrogallol (PYRO), a specific generator of superoxide anion and H2O2, revealed no phenotypical differences, particularly in cell death, as compared with DMSO treatment. These findings strongly suggest that ROS may not play a pro-apoptotic role in MEF, although TIS21/BTG2 enhanced DOXO-induced H2O2 generation both in HeLa and MEF cells. In summary, BTG2/TIS21 worked as an enhancer of DOXO-induced cell death in HeLa, but anti-apoptotic in MEF.
DISCUSSION
We demonstrated here that induction of BTG2/TIS21/PC3 expression sensitized HeLa cells to DOXO-mediated cell death via imbalance of antioxidant enzyme, e.g. induction of MnSOD, but not catalase and GPx, thereby resulting in H2O2 generation (Fig. 7). The phenomenon was confirmed by infections of Ad-TIS21 virus and lentivirus carrying sh-BTG2 RNA, in addition to treatments of NAC and membrane-permeable catalase. The mechanism of significant induction of BTG2/TIS21/PC3 expression after DOXO treatment (Fig. 1C) could be well supported by the presence of four tandem PuPuPuC(A/T) pentamer, a potential p53 recognition element (32), on the 5′-untranslated region of BTG2 gene (4). DOXO-induced BTG2 expression has been known to be p53-dependent in MCF-7 cells (33), whereas 12-O-tetradecanoylphorbol-13-acetate induces BTG2 expression in U937 cells p53-independently (10). Furthermore, infection of HeLa cells with Ad-TIS21 virus significantly enhanced DOXO-induced HeLa cell death (Fig. 2, A and B), whereas sh-BTG2 RNA in lentivirus reduced apoptosis (Fig. 2C), strongly supporting a pro-apoptotic role for BTG2/TIS21/PC3 in cancer cells, not only HeLa cells but also Huh7, HepG2, and Hep3B cells (Fig. 2D).
It has been known that DOXO induces ROS generation by utilizing cellular oxidoreductases (34, 35), such as NADH dehydrogenase complex, NADPH cytochrome p450 reductase (36), and xanthine oxidase, as well as by nonenzymatic pathways via complex formation between DOXO-ferric iron (37); electron donor activates benzanthraquinones of DOXO to semiquinones, and a single electron is transferred to molecular oxygen, thereby generating free radicals, such as superoxide anion, H2O2, hydroxyl radical, and other reactive nitrogen-species (38). Indeed, treatment of HeLa cells with DOXO generated ROS (Fig. 3A), and DOXO-induced H2O2 generation was significantly regulated by TIS21 expression, e.g. increased by Ad-TIS21 infection (Fig. 3E) but decreased by sh-BTG2/TIS21 RNA and NAC treatment (Fig. 3F). Oxidative damage, therefore, has long been considered to be an important mechanism of anthracycline activity in tumor cells (27). In the present study, DOXO-induced chromatin condensation and cleavage of lamin A/C were aggravated by introduction of TIS21 to HeLa cells, however, pretreatment of the cells with NAC significantly reduced the damage by DOXO (Fig. 4), supporting the idea that TIS21 works as a pro-apoptotic molecule by enhancing ROS generation upon the treatment of cancer cells with DOXO. When we employed PYRO, TIS21 also enhanced PYRO-induced HeLa cell death; however, it was completely blocked by NAC pretreatment (Fig. 3D). The data strongly suggest that TIS21 enhanced PYRO-induced superoxide and its conversion to H2O2.
In addition to ROS generation, MnSOD has recently been identified as a potential target of p53, and ROS have been identified as downstream mediators of tumor suppressor p53 (39). Therefore, it is rather tempting to postulate that DOXO induces p53 activation and BTG2/TIS21/PC3 expression, which in turn up-regulates ROS generation and enhances cell death. Indeed, infection of HeLa cells with Ad-TIS21 itself up-regulated MnSOD expression before DOXO treatment, and the expression of MnSOD, but not catalase, GPx, and CuZnSOD, was additively increased after DOXO treatment caused by endogenous BTG2 and exogenous TIS21 activities (Fig. 5, B and C). Thus, a question arises of why high induction of MnSOD enhanced DOXO-induced cell death. Even though the role of SOD as an antioxidant defense has been extensively documented, high activities of SOD have sometimes been reported to be toxic in vivo (40); therefore the higher the level of SOD, the greater the rate of accumulation of H2O2 (41). Furthermore, up-regulation of MnSOD has been shown to induce and inhibit apoptotic effects of c-Rel in the same cells (42, 43).
In this study, we presented pro-apoptotic role of BTG2 in the DOXO-induced cancer cell death. However, that is in conflict with a previous report regarding the anti-apoptotic effect of BTG2/PC3/TIS21 in ES cells (4). We therefore employed TIS21–/– MEF and confirmed that TIS21 enhanced DOXO-induced H2O2 generation not only in cancer cells but also in MEF; however, the cellular response to H2O2 was quite different between cancer and normal cells (Fig. 6). This conflict can be well supported by the report that the effect of ROS in cells is quite different based on the cellular context; mitogenic response, growth arrest, senescence, and cell death (44). We cannot presently explain why H2O2 produced by TIS21 shows such a different effect on cell death between cancer cells and embryonic cells. However, as far as we know, this is the first report to show that BTG2 enhances DOXO-induced cancer cell death via up-regulation of MnSOD. Therefore, we suggest that BTG2TIS21/PC3 augments DOXO-induced cancer cell death via deregulation of antioxidant enzymes, resulting in increased susceptibility to DOXO-induced oxidative damage.
This work was supported by Research Grants R01-2006-000-10311-0 and M10756040001-07N5604-00110 from the Korea Science and Engineering Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Footnotes
The abbreviations used are: ROS, reactive oxygen species; DOXO, doxorubicin; PARP, poly(ADP-ribose) polymerase; NAC, N-acetyl-l-cysteine; MnSOD, manganese-superoxide dismutase; GPx, glutathione peroxidase 1; H2-DCFDA, 2,7-dichlorodihydrofluorescein diacetate; PYRO, pyrogallol; shRNA, short hairpin RNA; DMSO, dimethyl sulfoxide; PEG, polyethylene glycol; RT, reverse transcription; HA, hemagglutinin; NBT, nitro blue tetrazolium salt; Ad-β-Gal, adenovirus with bacterial β-galactosidase; m.o.i., multiplicity of infection; MEF, mouse embryonic fibroblast(s).
References
- 1.Lim, R. W., Varnum, B. C., and Herschman, H. R. (1987) Oncogene 1 263–270 [PubMed] [Google Scholar]
- 2.Fletcher, B. S., Lim, R. W., Varnum, B. C., Kujubu, D. A., Koski, R. A., and Herschman, H. R. (1991) J. Biol. Chem. 266 14511–14518 [PubMed] [Google Scholar]
- 3.Bradbury, A., Possenti, R., Shooter, E. M., and Tirone, F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88 3353–3357 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Rouault, J. P., Falette, N., Guehenneux, F., Guillot, C., Rimokh, R., Wang, Q., Berthet, C., Moyret-Lalle, C., Savatier, P., Pain, B., Shaw, P., Berger, R., Samarut, J., Magaud, J. P., Ozturk, M., Samarut, C., and Puisieux, A. (1996) Nat. Genet. 14 482–486 [DOI] [PubMed] [Google Scholar]
- 5.Lim, I. K., Lee, M. S., Lee, S. H., Kim, N. K., Jou, I., Seo, J. S., and Park, S. C. (1995) J Cancer Res. Clin. Oncol. 121 279–284 [DOI] [PubMed] [Google Scholar]
- 6.Struckmann, K., Schraml, P., Simon, R., Elmenhorst, K., Mirlacher, M., Kononen, J., and Moch, H. (2004) Cancer Res. 64 1632–1638 [DOI] [PubMed] [Google Scholar]
- 7.Ficazzola, M. A., Fraiman, M., Gitlin, J., Woo, K., Melamed, J., Rubin, M. A., and Walden, P. D. (2001) Carcinogenesis 22 1271–1279 [DOI] [PubMed] [Google Scholar]
- 8.Boiko, A. D., Porteous, S., Razorenova, O. V., Krivokrysenko, V. I., Williams, B. R., and Gudkov, A. V. (2006) Genes Dev. 20 236–252 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lim, I. K., Lee, M. S., Ryu, M. S., Park, T. J., Fujiki, H., Eguchi, H., and Paik, W. K. (1998) Mol. Carcinog. 23 25–35 [DOI] [PubMed] [Google Scholar]
- 10.Ryu, M. S., Lee, M. S., Hong, J. W., Hahn, T. R., Moon, E., and Lim, I. K. (2004) Exp. Cell Res. 299 159–170 [DOI] [PubMed] [Google Scholar]
- 11.Hong, J. W., Ryu, M. S., and Lim, I. K. (2005) J. Biol. Chem. 280 21256–21263 [DOI] [PubMed] [Google Scholar]
- 12.Fridovich, I. (1995) Annu. Rev. Biochem. 64 97–112 [DOI] [PubMed] [Google Scholar]
- 13.Zelko, I. N., Mariani, T. J., and Folz, R. J. (2002) Free Radic. Biol. Med. 33 337–349 [DOI] [PubMed] [Google Scholar]
- 14.Li, Y., Huang, T. T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., Wallace, D. C., and Epstein, C. J. (1995) Nat. Genet. 11 376–381 [DOI] [PubMed] [Google Scholar]
- 15.Scott, M. D., Meshnick, S. R., and Eaton, J. W. (1987) J. Biol. Chem. 262 3640–3645 [PubMed] [Google Scholar]
- 16.Scott, M. D., Meshnick, S. R., and Eaton, J. W. (1989) J. Biol. Chem. 264 2498–2501 [PubMed] [Google Scholar]
- 17.Li, N., Oberley, T. D., Oberley, L. W., and Zhong, W. (1998) Prostate 35 221–233 [DOI] [PubMed] [Google Scholar]
- 18.Chen, J. G., Yang, C. P., Cammer, M., and Horwitz, S. B. (2003) Cancer Res. 63 7891–7899 [PubMed] [Google Scholar]
- 19.Islaih, M., Halstead, B. W., Kadura, I. A., Li, B., Reid-Hubbard, J. L., Flick, L., Altizer, J. L., Thom Deahl, J., Monteith, D. K., Newton, R. K., and Watson, D. E. (2005) Mutat. Res. 578 100–116 [DOI] [PubMed] [Google Scholar]
- 20.Tirone, F. (2001) J. Cell Physiol. 187 155–165 [DOI] [PubMed] [Google Scholar]
- 21.Lee, Y., and Shacter, E. (1997) Blood 89 4480–4492 [PubMed] [Google Scholar]
- 22.Kim, H. S., Song, M. C., Kwak, I. H., Park, T. J., and Lim, I. K. (2003) J. Biol. Chem. 278 37497–37510 [DOI] [PubMed] [Google Scholar]
- 23.Serrander, L., Cartier, L., Bedard, K., Banfi, B., Lardy, B., Plastre, O., Sienkiewicz, A., Fórró, L., Schlegel, W., and Krause, K. (2007) Biochem. J. 406 105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Park, T. J., Kim, J. Y., Oh, S. P., Kang, S. Y., Kim, B. W., Wang, H. J., Song, K. Y., Kim, H. C., and Lim, I. K. (2008) Hepatology 47 1533–1543 [DOI] [PubMed] [Google Scholar]
- 25.Zaleskis, G., Berleth, E., Verstovsek, S., Ehrke, M. J., and Mihich, E. (1994) Mol. Pharmacol. 46 901–908 [PubMed] [Google Scholar]
- 26.Lee, T. K., Lau, T. C., and Ng, I. O. (2002) Cancer Chemother. Pharmacol. 49 78–86 [DOI] [PubMed] [Google Scholar]
- 27.Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., and Gianni, L. (2004) Pharmacol. Rev. 56 185–229 [DOI] [PubMed] [Google Scholar]
- 28.Kim, S. W., Han, Y. W., Lee, S. T., Jeong, H. J., Kim, S. H., Kim, I. H., Lee, S. O., Kim, D. G., Kim, S. Z., and Park, W. H. (2008) Mol. Carcinog. 47 114–125 [DOI] [PubMed] [Google Scholar]
- 29.Beckman, J. S., Minor, R. L., Jr., White, C. W., Repine, J. E., Rosen, G. M., and Freeman, B. A. (1988) J. Biol. Chem. 263 6884–6892 [PubMed] [Google Scholar]
- 30.Park, S., Lee, Y. J., Lee, H. J., Seki, T., Hong, K. H., Park, J., Beppu, H., Lim, I. K., Yoon, J. W., Li, E., Kim, S. J., and Oh, S. P. (2004) Mol. Cell Biol. 24 10256–10262 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Kim, B. C., Ryu, M. S., Oh, S. P., and Lim, I. K. (2008) Stem Cells 26 2339–2348 [DOI] [PubMed] [Google Scholar]
- 32.el-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1 45–49 [DOI] [PubMed] [Google Scholar]
- 33.Cortes, U., Moyret-Lalle, C., Falette, N., Duriez, C., Ghissassi, F. E., Barnas, C., Morel, A. P., Hainaut, P., Magaud, J. P., and Puisieux, A. (2000) Mol. Carcinog. 27 57–64 [PubMed] [Google Scholar]
- 34.Vasquez-Vivar, J., Martasek, P., Hogg, N., Masters, B. S., Pritchard, K. A., Jr., and Kalyanaraman, B. (1997) Biochemistry 36 11293–11297 [DOI] [PubMed] [Google Scholar]
- 35.Minotti, G., Cairo, G., and Monti, E. (1999) FASEB J. 13 199–212 [PubMed] [Google Scholar]
- 36.Bachur, N. R., Gordon, S. L., Gee, M. V., and Kon, H. (1979) Proc. Natl. Acad. Sci. U. S. A. 76 954–957 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Eliot, H., Gianni, L., and Myers, C. (1984) Biochemistry 23 928–936 [DOI] [PubMed] [Google Scholar]
- 38.Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., and Schlattner, U. (2006) J. Mol. Cell Cardiol. 41 389–405 [DOI] [PubMed] [Google Scholar]
- 39.Pani, G., Bedogni, B., Anzevino, R., Colavitti, R., Palazzotti, B., Borrello, S., and Galeotti, T. (2000) Cancer Res. 60 4654–4660 [PubMed] [Google Scholar]
- 40.Gardner, R., Salvador, A., and Moradas-Ferreira, P. (2002) Free Radic. Biol. Med. 32 1351–1357 [DOI] [PubMed] [Google Scholar]
- 41.Buettner, G. R., Ng, C. F., Wang, M., Rodgers, V. G., and Schafer, F. Q. (2006) Free Radic. Biol. Med. 41 1338–1350 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bernard, D., Quatannens, B., Begue, A., Vandenbunder, B., and Abbadie, C. (2001) Cancer Res. 61 2656–2664 [PubMed] [Google Scholar]
- 43.Bernard, D., Monte, D., Vandenbunder, B., and Abbadie, C. (2002) Oncogene 21 4392–4402 [DOI] [PubMed] [Google Scholar]
- 44.Martindale, J. L., and Holbrook, N. J. (2002) J. Cell Physiol. 192 1–15 [DOI] [PubMed] [Google Scholar]